DexComvs.Insulet
DXCM vs PODD · both in Diabetes & metabolic disease, part of the Medicine, pharma & life science value chain: Treatment and monitoring of diabetes and metabolic disease — from insulin to glucose monitoring.
DexCom is about 2.6× larger than Insulet by market cap; DexCom trades at the lower P/E (31.1 vs 36.9); year to date, DexCom leads (+12.9% vs −43.3%).
Side by side
| DXCM | PODD | |
|---|---|---|
| Market cap | $28.9B | $11.2B |
| Price | $74.96 | $161.28 |
| Today | +2.7% | +1.9% |
| Return YTD | +12.9% | −43.3% |
| Return 1Y | −12.3% | −45.8% |
| P/E | 31.1 | 36.9 |
| P/S | 6.0 | 3.9 |
| P/B | 9.8 | 7.4 |
Data as of 2026-07-11 · updates daily after U.S. close
The two companies
DexComDXCM
American medtech company focused on continuous glucose monitoring (CGM) for people with diabetes.
Full DXCM profile →InsuletPODD
American medtech company known for Omnipod — a tubeless insulin pump for diabetes management.
Full PODD profile →More comparisons in Diabetes & metabolic disease
See where DXCM and PODD sit in the full Medicine, pharma & life science map — every segment from suppliers to end markets.Open the Life science value chain →